Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial

  • Cady R
  • Ryan R
  • Jhingran P
 et al. 
  • 10

    Readers

    Mendeley users who have this article in their library.
  • 89

    Citations

    Citations of this article.

Abstract

Objective To evaluate the impact of sumatriptan succinate injection compared with placebo on productivity loss during a migraine attack in the workplace. Design Randomized, double-blind, placebo-controlled, parallel-group clinical trial. Setting Fifteen clinical centers in the United States. Patients One hundred thirty-five patients 18 years and older diagnosed as having migraine according to International Headache Society criteria. Interventions Patients self-administered sumatriptan injection (6 mg) or matching placebo to treat a moderate or severe migraine occurring within the first 4 hours of a minimum 8-hour work shift. Main Outcome Measures Mean productivity loss 2 hours after dosing and across the work shift; percentages of patients returning to normal work performance within 2 hours after dosing and across the work shift; percentages of patients experiencing headache relief (reduction of moderate or severe predose pain to mild or no pain) 1 and 2 hours after dosing. Results Mean productivity loss was significantly (P[<=].002) lower in the sumatriptan group compared with the placebo group both during the 2-hour postdose period (sumatriptan, 39 minutes; placebo, 54 minutes) and across the work shift (sumatriptan, 86 minutes; placebo, 168 minutes). Significantly (P

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Roger C. Cady

  • Robert Ryan

  • Priti Jhingran

  • Stephen O'Quinn

  • D. Gayla Pait

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free